ABSTRACT
Although retinoids are considered as the most effective treatment, management of dissecting cellulitis of the scalp (DCS) is often challenging. A multicentre retrospective study was conducted to evaluate the efficacy of anti-tumour necrosis factor (TNF) agents in treating DCS after failure of other conventional treatments. Twenty-six patients were included. After a mean treatment duration of 19â months (SD 21), the median Physician's Global Assessment score decreased from 3 to 1. The median number of inflammatory nodules and abscesses decreased from 7 to 0.5 and from 1 to 0, respectively. The median Dermatology Life Quality Index and numerical rating scale score for pain severity decreased from 10 to 8 and 6 to 1, respectively. The median treatment satisfaction was 7 out of 10 on the Patient Satisfaction Index. This study confirms the efficacy of anti-TNF agents in treating patients with DCS that is resistant to conventional therapies.
Subject(s)
Scalp Dermatoses , Tumor Necrosis Factor Inhibitors , Humans , Retrospective Studies , Cellulitis/drug therapy , Cellulitis/pathology , Scalp Dermatoses/drug therapy , Tumor Necrosis Factor-alphaABSTRACT
Dupilumab is a therapeutic antibody targeting IL-4 and IL-13 receptor subunit alpha used for the treatment of patients with atopic dermatitis (AD). Cases of psoriasis-like reactions induced under dupilumab treatment (dupilumab-induced psoriatic eruption [DI-Pso]) for AD were recently reported. To understand the pathogenesis of DI-Pso, we performed gene expression profiling studies on skin biopsies of DI-Pso (n = 7) compared with those of plaque psoriasis, AD, and healthy controls (n = 4 each). Differential gene expression was performed using enrichment and Gene Ontology analysis. Gene expression was validated by qPCR, and protein levels were assessed by immunohistochemistry. Transcriptomic and protein analysis of DI-Pso compared with that of healthy controls, plaque psoriasis, and AD skins revealed activation of T helper 17/IL-23 pathways associated with a significant expression of IL-36, surrogate marker of pustular psoriasis. By contrast, T helper 2 representative genes' expression was strongly decreased in DI-Pso across comparison. Matching analysis with public data of pustular psoriasis skin corroborated that DI-Pso and pustular psoriasis upstream regulators overlap, greater than the overlap with plaque psoriasis. Furthermore, DI-Pso showed strongly decreased expression of many barrier skin genes compared with healthy controls, plaque psoriasis, and AD. Our data indicate that the pathogenesis of DI-Pso relied on a shift of skin immune responses from a T helper 2 to an IL-36 and T helper 17 polarization and on intensified skin barrier alterations.
Subject(s)
Dermatitis, Atopic , Exanthema , Psoriasis , Humans , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/genetics , Interleukin-4/genetics , Interleukin-13/genetics , Psoriasis/drug therapy , Psoriasis/geneticsABSTRACT
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement. To evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation. This retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients' medical records. Univariate logistic regression analysis, with an estimation of unadjusted odds ratios (OR) and their 95% CI ,was performed to identify factors associated with complete cutaneous remission (CR), followed by multivariate logistic regression analysis. At one year, 43 of the 120 (36%) included patients had CR. The best response rates were obtained with oral corticosteroids (12/21, 57%), followed by a combination of hydroxychloroquine and topical steroids (6/13, 46%). In multivariate analysis, lupus pernio was the only predictor of a poor cutaneous response. We suggest the use of a combination of hydroxychloroquine and topical steroids as an optimal first-line treatment for cutaneous sarcoidosis, given the known adverse effects of systemic corticosteroids.
Subject(s)
Sarcoidosis , Skin Diseases , Humans , Retrospective Studies , Hydroxychloroquine/therapeutic use , Skin Diseases/pathology , Sarcoidosis/pathology , Adrenal Cortex Hormones/therapeutic use , SteroidsSubject(s)
Fasciitis, Necrotizing , Soft Tissue Infections , Abdomen , Commerce , Humans , Internet , Soft Tissue Infections/drug therapyABSTRACT
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition substantially impacting patients' quality of life; the pathogenesis remains unclear, and treatment is complex and not yet standardized. Observational data are increasingly being used to evaluate therapeutics in "real-life" interventions, and the development of e-cohorts is offering new tools for epidemiological studies at the population level. OBJECTIVE: The aim of this study was to describe the clinical characteristics and treatment history of HS participants in the Community of Patients for Research (ComPaRe) cohort and to compare these to other cohorts. METHODS: We performed a cross-sectional study of the baseline data of HS participants in ComPaRe, an e-cohort of patients with chronic diseases. Data were collected using patient-reported questionnaires about clinical-dem-ographic aspects, quality of life, and treatment history. RESULTS: A total of 396 participants (339 females, 57 males) were included (mean age 38 years); 83 (21%) had a family history of HS, 227 (57.3%) were current smokers, and 241 (60.9%) were overweight or obese. Most of the participants declared a Hurley stage II (n = 263, 66.4%) or III (n = 76, 20.3%). The breast was more frequently affected in women than men (37.5 vs. 5.3%, p < 0.0001), whereas the dorsal region was more frequently affected in men (39.5 vs. 10.9%, p < 0.0001). Increased disease stage was associated with obesity (25.9 vs. 33.8 vs. 51.3%, p = 0.02) and some HS localizations (genital [p < 0.005], pubis [p < 0.007], gluteal fold [p = 0.02], and groin [p < 0.0001]). The most frequently prescribed treatments were oral antibiotics (n = 362, 91.4%), especially amoxicillin-clavulanic acid and cyclins. Less than 10% of participants received biologics. Most of these results were consistent with previously published cohorts. CONCLUSION: Recruitment of participants by such a web platform can be a faster way to get relevant scientific data for a wide variety of patients that could be used for epidemiological studies and to evaluate therapeutics in "real-life" interventions.
Subject(s)
Hidradenitis Suppurativa/complications , Hidradenitis Suppurativa/therapy , Adult , Cohort Studies , Female , France , Hidradenitis Suppurativa/epidemiology , Humans , Male , Quality of Life , Severity of Illness Index , Sociodemographic Factors , Young AdultABSTRACT
Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease. HS appears to be a primary abnormality in the pilosebaceous-apocrine unit. In this work, we characterized hair follicle stem cells (HFSCs) isolated from HS patients and more precisely the outer root sheath cells (ORSCs). We showed that hair follicle cells from HS patients had an increased number of proliferating progenitor cells and lost quiescent stem cells. Remarkably, we also showed that the progression of replication forks was altered in ORSCs from hair follicles of HS patients, leading to activation of the ATR/CHK1 pathway. These alterations were associated with an increased number of micronuclei and with the presence of cytoplasmic ssDNA, leading to the activation of the IFI16/STING pathway and the production of type I IFNs. This mechanistic analysis of the etiology of HS in the HFSC compartment establishes a formal link between genetic predisposition and skin inflammation observed in HS.
Subject(s)
DNA Damage , DNA Replication , Hair Follicle/metabolism , Hidradenitis Suppurativa/metabolism , Membrane Proteins/metabolism , Nuclear Proteins/metabolism , Phosphoproteins/metabolism , Stem Cells/metabolism , Adolescent , Adult , Ataxia Telangiectasia Mutated Proteins/metabolism , Checkpoint Kinase 1/metabolism , Female , Hair Follicle/pathology , Hidradenitis Suppurativa/pathology , Humans , Inflammation/metabolism , Inflammation/pathology , Male , Middle Aged , Stem Cells/pathologySubject(s)
Hidradenitis Suppurativa/drug therapy , Immunosuppressive Agents/therapeutic use , Thalidomide/therapeutic use , Adolescent , Adult , Female , Hidradenitis Suppurativa/diagnosis , Hidradenitis Suppurativa/immunology , Humans , Male , Remission Induction , Retrospective Studies , Severity of Illness Index , Treatment Outcome , Young AdultSubject(s)
Down Syndrome/epidemiology , Hidradenitis Suppurativa/epidemiology , Adolescent , Adult , Aged , Child , Comorbidity , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Prevalence , Young AdultSubject(s)
Lymphoma, T-Cell, Cutaneous/diagnosis , Pityriasis Lichenoides/diagnosis , Pityriasis Lichenoides/pathology , Skin Neoplasms/diagnosis , Skin/pathology , CD8-Positive T-Lymphocytes/pathology , Diagnosis, Differential , Female , Fever/etiology , Humans , Middle Aged , Necrosis/etiology , Pityriasis Lichenoides/complications , Skin Ulcer/etiologyABSTRACT
Cyclosporine has shown promising results for mortality in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. However, available studies included only a small number of patients and did not include a validated and homogenous control group. We present the results from a retrospective monocentric study including 174 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis during 2005-2016. Among them, 95 received cyclosporine (3 mg/kg/day) plus supportive care, and 79 received supportive care only. Both a traditional exposed/unexposed method and a propensity score-matching method were used to compare the progression of skin detachment between day 0 and day 5, the proportion of patients with cutaneous re-epithelialization starting on day 5 or mucosal re-epithelialization on day 10, the duration of progression, and the number of deaths between the two groups. None of these outcomes significantly favored cyclosporine, either by the exposed/unexposed method or the propensity score method. Acute renal failure affected more patients receiving cyclosporine (P = 0.05). Overall, the results of this epidemiological study did not show a beneficial effect of cyclosporine in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. They are discordant with those previously published. The large number of patients and the use of a propensity score method provide valuable insights. The main limitation of the study is the lack of randomization.
Subject(s)
Acute Kidney Injury/epidemiology , Cyclosporine/therapeutic use , Immunosuppressive Agents/therapeutic use , Palliative Care , Re-Epithelialization/drug effects , Stevens-Johnson Syndrome/therapy , Acute Kidney Injury/etiology , Adult , Cyclosporine/pharmacology , Disease Progression , Female , Humans , Immunosuppressive Agents/pharmacology , Male , Middle Aged , Propensity Score , Re-Epithelialization/immunology , Retrospective Studies , Skin/drug effects , Skin/immunology , Skin/pathology , Stevens-Johnson Syndrome/complications , Stevens-Johnson Syndrome/immunology , Stevens-Johnson Syndrome/mortality , Survival Analysis , Treatment FailureSubject(s)
Pregnancy Complications/drug therapy , Pyrimethamine/therapeutic use , Stevens-Johnson Syndrome/drug therapy , Sulfadiazine/therapeutic use , Toxoplasmosis/drug therapy , Adult , Cesarean Section , Female , Follow-Up Studies , Gestational Age , Humans , Infant, Newborn , Pregnancy , Pregnancy Complications/diagnosis , Prenatal Diagnosis/methods , Pyrimethamine/adverse effects , Rare Diseases , Risk Assessment , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/physiopathology , Sulfadiazine/adverse effects , Toxoplasmosis/diagnosis , Treatment OutcomeSubject(s)
Ovarian Neoplasms/radiotherapy , Paraneoplastic Syndromes/physiopathology , Pemphigus/etiology , Radiodermatitis/diagnosis , Biopsy, Needle , Diagnosis, Differential , Disease Progression , Enzyme-Linked Immunosorbent Assay/methods , Fatal Outcome , Female , Fluorescent Antibody Technique, Indirect , Humans , Immunohistochemistry , Middle Aged , Ovarian Neoplasms/pathology , Palliative Care/methods , Paraneoplastic Syndromes/drug therapy , Pemphigus/drug therapy , Pemphigus/pathology , Radiodermatitis/drug therapy , Risk AssessmentABSTRACT
Hidradenitis suppurativa (HS) is a chronic, inflammatory, debilitating, follicular disease of the skin. Despite a high prevalence in the general population, the physiopathology of HS remains poorly understood. The use of antibiotics and immunosuppressive agents for therapy suggests a deregulated immune response to microflora. Using cellular and gene expression analyses, we found an increased number of infiltrating CD4(+) T cells secreting IL-17 and IFN-γ in perilesional and lesional skin of patients with HS. By contrast, IL-22-secreting CD4(+) T cells are not enriched in HS lesions contrasting with increased number of those cells in the blood of patients with HS. We showed that keratinocytes isolated from hair follicles of patients with HS secreted significantly more IL-1ß, IP-10, and chemokine (C-C motif) ligand 5 (RANTES) either constitutively or on pattern recognition receptor stimulations. In addition, they displayed a distinct pattern of antimicrobial peptide production. These findings point out a functional defect of keratinocytes in HS leading to a balance prone to inflammatory responses. This is likely to favor a permissive environment for bacterial infections and chronic inflammation characterizing clinical outcomes in patients with HS.
Subject(s)
Cytokines/metabolism , Hidradenitis Suppurativa/blood , Inflammation/physiopathology , Keratinocytes/metabolism , Adult , Cells, Cultured , Cytokines/immunology , Disease Progression , Female , Flow Cytometry , Hidradenitis Suppurativa/physiopathology , Humans , Inflammation/metabolism , Keratinocytes/pathology , Male , Microarray Analysis/methods , RNA/metabolism , Risk Assessment , Sampling Studies , Statistics, Nonparametric , Young AdultSubject(s)
Burkitt Lymphoma/diagnosis , Skin/pathology , Aged , Arm , Diagnosis, Differential , Female , Humans , Skin Neoplasms/diagnosisSubject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Cryptococcosis/complications , Cryptococcus neoformans , Lung Diseases, Fungal/complications , Opportunistic Infections/complications , Sezary Syndrome/complications , Sezary Syndrome/drug therapy , Skin Neoplasms/drug therapy , Aged , Alemtuzumab , Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Agents/administration & dosage , Cryptococcosis/drug therapy , Female , Humans , Lung Diseases, Fungal/drug therapy , Opportunistic Infections/drug therapySubject(s)
Giant Cell Arteritis/pathology , Nose/pathology , Aged, 80 and over , Anti-Inflammatory Agents/therapeutic use , Giant Cell Arteritis/drug therapy , Giant Cell Arteritis/surgery , Humans , Male , Methylprednisolone/therapeutic use , Necrosis , Nose/surgery , Prednisone/therapeutic use , Rhinoplasty , Thrombosis/surgeryABSTRACT
BACKGROUND: Specific cutaneous lesions of Waldenström macroglobulinemia are rare and include neoplastic cell infiltrates, IgM bullous disease, and so-called IgM-storage papules, which characterize cutaneous macroglobulinosis (CM). OBSERVATIONS: We report 2 patients with CM. In patient 1, CM started as small papules, as reported in most of the previously published case studies of CM. In patient 2, lesion evolution was remarkable by its severity, with large ulcerated nodules, and the disease progressed rapidly. As mentioned for half the previously described patients, peripheral neuropathy was suspected in patient 2 and demonstrated in patient 1, with production of antibodies to myelin-associated glycoprotein. CONCLUSIONS: To the best of our knowledge, rituximab treatment of Waldenström macroglobulinemia associated with CM has not been described previously. Rituximab caused complete remission of the lesions in patient 1, whereas disease rapidly progressed in patient 2, and the patient died. These observations suggest that evolution of the cutaneous IgM-storage lesions reflects that of the underlying Waldenström macroglobulinemia, and CM is not a prognostic marker.
Subject(s)
Skin Diseases/etiology , Skin Diseases/pathology , Waldenstrom Macroglobulinemia/pathology , Aged , Humans , Male , Skin Diseases/therapy , Waldenstrom Macroglobulinemia/complications , Waldenstrom Macroglobulinemia/therapyABSTRACT
Quinolone-resistant Neisseria gonorrhoeae rates have increased worldwide since 1994. The objective of this study was to appraise: (i) the antimicrobial susceptibility of Neisseria gonorrhoeae in a venereology clinic in Paris, between 2005 and 2007; and (ii) the factors associated with quinolone-resistant N. gonorrhoeae. A prospective study of consecutive cases was performed for the period 2005 to 2007. Susceptibility of N. gonorrhoeae to five antibiotics (ciprofloxacin, ceftriaxone, spectinomycin, penicillin G and tetracycline) was tested systematically. Clinical and epidemiological data were collected using a standardized form. Male-to-female sex ratio was 22.0. Median age was 30.0 years. Of 115 cases, 84 occurred in men having sex with men (72.6%) and 22 involved the anorectal area (19.1%). The rate of quinolone-resistant N. gonorrhoeae was 37.4% (43/115), without significant association with gender, age, sexual behaviour, past history of sexually transmitted diseases and susceptibility to other antibiotics. All N. gonorrhoeae were susceptible to ceftriaxone and spectinomycin. The rate of quinolone-resistant N. gonorrhoeae in Paris has been increasing since 2004. Ceftriaxone remains the gold standard treatment.